Latest Breaking News On - Institute of microbiology chinese academy science - Page 10 : comparemela.com

February 10, 2021 Etesevimab (JS016) Administered with Bamlanivimab Receives FDA Emergency Use Authorization for COVID-19 GlobeNewswire February 10, 2021 Etesevimab and bamlanivimab administered together is authorized for treatment of recently diagnosed, mild to moderate COVID-19 in patients who are high risk for progression to severe COVID-19 More than 250,000 doses manufactured throughout Q1 2021; up to 1 million doses by mid-2021 FDA authorizes shortened infusion time for this neutralizing antibody therapy authorized for emergency use SHANGHAI, China, Feb. 10, 2021 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for investigational etesevimab (JS016 or LY-CoV016) 1400 mg and bamlanivimab (LY-CoV555) 700 mg togeth

Puerto ricoUnited statesHong kongSan franciscoJunshi biosciencesEli lillyVaccine research centerInstitute of microbiology chinese academy scienceInstitute of microbiologyIr teamNational institute of allergyChinese academy of scienceDrug administrationJournal of the american medical associationPr teamBamlanivimab receives